Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578


Delayed Quote. Delayed  - 07/22 05:39:37 pm
76.6 EUR   +0.50%
07/22 PROMIS NEUROSCI : Announces Appointment of Dr. Johanne Kaplan as Chi..
07/21 SANOFI : Information concerning the total number of voting rights an..
07/21 JUNIPER PHARMAC : Appoints Alicia Secor President and Chief Executiv..
News SummaryMost relevantAll newsSector news 

Sanofi's Genzyme Says MS Drug Lemtrada Shows More Trial Success

share with twitter share with LinkedIn share with facebook
share via e-mail
04/24/2012 | 09:39pm CEST

Genzyme, the U.S. biotechnology unit of France's Sanofi SA (SNY), Tuesday said latest results from a late-stage clinical study showed its multiple sclerosis drug Lemtrada significantly reduced relapses and any worsening of the condition, and in some cases showed a reversal in disability.

In a Phase III trial called CARE-MS II involving 840 patients, the relapse rate was reduced by 49%, compared with an older drug called Rebif, or subcutaneous interferon beta-1a, which is sold by German rival Merck KGaA (>> Merck KGaA).

The company said 65% of patients treated with Lemtrada were relapse-free after two years into the study, compared with 47% treated with Rebif.

Genzyme is developing the drug, also known as alemtuzumab, in collaboration with German drug maker Bayer AG (>> Bayer AG), and Sanofi aims to launch the drug by the end of next year. Multiple sclerosis is a chronic disease that attacks the central nervous system.

"We believe these ground-breaking results from CARE-MS II, including reversal of disability accumulation in some patients, achieved over the standard therapy Rebif, provide a message of hope for people living with MS," said David Meeker, Genzyme's CEO, said in a statement, adding: "We are on track to submit alemtuzumab for review to U.S. and EU regulatory authorities in the second quarter of this year."

In the CARE-MS II trial, alemtuzumab was given as an injection eight times over the course of the two-year study. The first treatment course of alemtuzumab was administered on five consecutive days, and the second course was administered on three consecutive days 12 months later. Rebif was administered by injection three times per week, each week, throughout the two years of study.

Sanofi, which is struggling with patent expiries on its blockbuster drugs, bought Genzyme in February 2011 in a bid to widen its research net.

--By Sten Stovall, Dow Jones Newswires; +44 207 842 9292; sten.stovall@dowjones.com

Stocks mentioned in the article : Merck KGaA, Bayer AG
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on SANOFI
07/22 PROMIS NEUROSCIENCES : Announces Appointment of Dr. Johanne Kaplan as Chief Deve..
07/21 SANOFI : Information concerning the total number of voting rights and shares, pr..
07/21 JUNIPER PHARMACEUTICALS : Appoints Alicia Secor President and Chief Executive Of..
07/20 JUNIPER PHARMACEUTICALS INC : Change in Directors or Principal Officers, Regulat..
07/15 SANOFI : Pasteur signs research agreement for Zika vaccine
07/14 MEDIVATION : Enters into Confidentiality Agreements, Including with Sanofi
07/14 SANOFI : Genzyme Begins Pivotal Phase 2/3 Trial of Olipudase Alfa for Adult Pati..
07/14 SANOFI : Patent Issued for Neutralizing Immunogen (NimIV) of Rhinovirus and Its ..
07/14 SANOFI : Army researchers team with Sanofi Pasteur to co-develop a Zika virus va..
07/14 FINDINGS FROM SANOFI PROVIDE NEW INS : Integration into Clinical...
More news
Sector news : Pharmaceuticals - NEC
07/22DJJOHNSON & JOHNSON : Acclarent Unit in $18 Million U.S. Settlement
07/22DJJOHNSON & JOHNSON : Acclarent Unit in $18 Million U.S. Settlement
07/22DJBAYER : 2Q 2016 -- Forecast
07/22DJMonsanto Wins EU Nod for New Biotech Soybeans
07/21DJBIOGEN : Announces CEO Search, Lifts Guidance--2nd Update
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
07/22 MannKind - Afrezza Sales Pacing Below My Bearish Line - Reality May Sting
07/22 Re-Evaluation Of LDL Cholesterol-Level Impacts Could Benefit Amarin's Vascepa
07/22 WALL STREET BREAKFAST : Markets Get First Glimpse Of Post-Brexit Data
07/22 More Zika worries
07/21 Big Pharma Dominates Healthcare But Caregivers Are Top Sector Yield Dogs In J..
Financials (€)
Sales 2016 37 117 M
EBIT 2016 9 360 M
Net income 2016 5 093 M
Debt 2016 5 594 M
Yield 2016 3,92%
P/E ratio 2016 18,60
P/E ratio 2017 16,10
EV / Sales 2016 2,81x
EV / Sales 2017 2,75x
Capitalization 98 592 M
More Financials
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 85,0 €
Spread / Average Target 11%
Consensus details
EPS Revisions
More Estimates Revisions
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
JÚr˘me Contamine Chief Financial Officer & EVP-Finance
Elias E. Zerhouni President-Global Research & Development
Yong-Jun Liu Head-Global Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI-3.03%108 205
JOHNSON & JOHNSON21.72%343 913
PFIZER INC.13.82%222 823
NOVARTIS AG-5.53%219 526
ROCHE HOLDING LTD.-9.55%218 832
MERCK & CO., INC.11.36%162 815
More Results